Table 3.

Sequence of medication usage (including current treatment) and median treatment duration with particular medications within each treatment pathway (in square brackets)

Treatment pathways and median treatment duration (months)	Frequency (%)
β-interferons [35]	36.0
β-interferons [35] -> dimethyl fumarate [11]	15.8
Glatiramer acetate [27]	13.0
Dimethyl fumarate [21]	10.8
β-interferons [24] -> teriflunomide [6*]	5.0
Glatiramer acetate [49] -> dimethyl fumarate [11]	5.0
β-interferons [26] -> glatiramer acetate [23]	2.9
β-interferons [35] -> glatiramer acetate [22] -> dimethyl fumarate [11]	2.9
β-interferons [63] -> dimethyl fumarate [4] -> β-interferons [3]	0.7
β-interferons [36] -> dimethyl fumarate [13] -> teriflunomide [2]	0.7
β-interferons [35] -> β-interferons [11] -> dimethyl fumarate [13]	1.4
β-interferons [35] -> β-interferons [11] -> teriflunomide [4]	0.7
β-interferons [30] -> dimethyl fumarate [10] -> glatiramer acetate [6]	1.4
β-interferons [17] -> glatiramer acetate [51] -> teriflunomide [4]	0.7
Dimethyl fumarate [16] -> teriflunomide [1]	0.7
Dimethyl fumarate [14] -> β-interferons [3]	0.7
Glatiramer acetate [59] -> teriflunomide [2]	0.7
Teriflunomide [10*]	0.7

Percentages do not sum to 100 due to rounding of values.

^*The median treatment duration may be underestimated due to the short period of drug availability.